Novel non-genomic signaling of thyroid hormone receptors in thyroid carcinogenesis

Molecular and Cellular Endocrinology

Volumn 308, Issue 1-2, 2009, Pages 63-69

  Guigon, Celine J ^a   Cheng, Sheue yann ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

catenin; Mouse model; Non genomic action; Phosphatidylinositol 3 kinase; Pituitary tumor transforming gene; Thyroid cancer; Thyroid hormone receptor mutants

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BETA CATENIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; RETINOID X RECEPTOR ALPHA; SECURIN; THYROID HORMONE RECEPTOR; THYROID HORMONE RECEPTOR ALPHA; THYROID HORMONE RECEPTOR BETA;

ANAPLASTIC CARCINOMA; ANEUPLOIDY; CANCER INVASION; CARCINOGENESIS; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; DISTANT METASTASIS; GENE MUTATION; HUMAN; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID HYPERPLASIA; TUMOR GROWTH;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AMINO ACID SEQUENCE; ANIMALS; BETA CATENIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM PROTEINS; ONCOGENES; RECEPTORS, THYROID HORMONE; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 67349251546     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2009.01.007     Document Type: Review

References (77)

1. Adams M., Matthews C., Collingwood T.N., Tone Y., Beck-Peccoz P., and Chatterjee K.K. Genetic analysis of 29 kindreds with generalized and pituitary resistance to thyroid hormone. Identification of thirteen novel mutations in the thyroid hormone receptor beta gene. J. Clin. Invest. 94 (1994) 506-515
2. Ando S., Sarlis N.J., Krishnan J., Feng X., Refetoff S., Zhang M.Q., Oldfield E.H., and Yen P.M. Aberrant alternative splicing of thyroid hormone receptor in a TSH-secreting pituitary tumor is a mechanism for hormone resistance. Mol. Endocrinol. 15 (2001) 1529-1538
3. Ando S., Sarlis N.J., Oldfield E.H., and Yen P.M. Somatic mutation of TRbeta can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. J. Clin. Endocrinol. Metab. 86 (2001) 5572-5576
4. Barlow C., Meister B., Lardelli M., Lendahl U., and Vennström B. Thyroid abnormalities and hepatocellular carcinoma in mice transgenic for v-erbA. EMBO J. 15 13 (1994) 4241-4250
5. Bronnegard M., Torring O., Boos J., Sylven C., Marcus C., and Wallin G. Expression of thyrotropin receptor and thyroid hormone receptor messenger ribonucleic acid in normal, hyperplastic, and neoplastic human thyroid tissue. J. Clin. Endocrinol. Metab. 79 (1994) 384-389
6. Cao X., Kambe F., Moeller L.C., Refetoff S., and Seo H. Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts. Mol. Endocrinol. 19 (2005) 102-112
7. Cheng S.-y. Thyroid hormone receptor mutations in cancer. Mol. Cell. Endocrinol. 213 (2003) 23-30
8. Cheng S.-y. Thyroid hormone receptor mutations and disease: beyond thyroid hormone resistance. Trends Endocrinol. Metab. 16 (2005) 176-182
9. Dace A., Zhao L., Park K.S., Furuno T., Takamura N., Nakanishi M., West B.L., Hanover J.A., and Cheng S. Hormone binding induces rapid proteasome-mediated degradation of thyroid hormone receptors. Proc. Natl Acad. Sci. U. S. A. 97 (2000) 8985-8990
10. Eng C. Role of PTEN, a lipid phosphatase upstream effector of protein kinase B, in epithelial thyroid carcinogenesis. Ann. N. Y. Acad. Sci. 968 (2002) 213-221
11. Furumoto H., Ying H., Chandramouli G.V., Zhao L., Walker R.L., Meltzer P.S., Willingham M.C., and Cheng S.-y. An unliganded thyroid hormone beta receptor activates the cyclin D1/cyclin-dependent kinase/retinoblastoma/E2F pathway and induces pituitary tumorigenesis. Mol. Cell. Biol. 25 (2005) 124-135
12. Furuya F., Guigon C.J., Zhao L., Lu C., Hanover J.A., and Cheng S.-y. Nuclear receptor corepressor is a novel regulator of phosphatidylinositol 3-kinase signaling. Mol. Cell. Biol. 27 (2007) 6116-6126
13. Furuya F., Hanover J.A., and Cheng S.-y. Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 1780-1785
14. Furuya F., Lu C., Willingham M.C., and Cheng S.-y. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Carcinogenesis 28 (2007) 2451-2458
15. Garcia-Rostan G., Tallini G., Herrero A., D'Aquila T.G., Carcangiu M.L., and Rimm D.L. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res. 59 (1999) 1811-1815
16. Guigon C.J., Zhao L., Lu C., Willingham M.C., and Cheng S.-y. Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor. Mol. Cell. Biol. 28 (2008) 4598-4608
17. Heaney A.P., Nelson V., Fernando M., and Horwitz G. Transforming events in thyroid tumorigenesis and their association with follicular lesions. J. Clin. Endocrinol. Metab. 86 (2001) 5025-5032
18. Heaney A.P., Singson R., McCabe C.J., Nelson V., Nakashima M., and Melmed S. Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet 355 (2000) 716-719
19. Hermanson O., Glass C.K., and Rosenfeld M.G. Nuclear receptor coregulators: multiple modes of modification. Trends Endocrinol. Metab. 13 (2002) 55-60
20. Hiroi Y., Kim H.H., Ying H., Furuya F., Huang Z., Simoncini T., Noma K., Ueki K., Nguyen N.H., Scanlan T.S., Moskowitz M.A., Cheng S.Y., and Liao J.K. Rapid nongenomic actions of thyroid hormone. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 14104-14109
21. Huber M.A., Kraut N., and Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 17 (2005) 548-558
22. Irvine R.F. Nuclear lipid signalling. Nat. Rev. Mol. Cell. Biol. 4 (2003) 349-360
23. Joensuu H., Klemi P., and Eerola E. DNA aneuploidy in follicular adenomas of the thyroid gland. Am. J. Pathol. 124 (1986) 373-376
24. Joensuu H., and Klemi P.J. DNA aneuploidy in adenomas of endocrine organs. Am. J. Pathol. 132 (1988) 145-151
25. Kamiya Y., Puzianowska-Kuznicka M., McPhie P., Nauman J., Cheng S.-y., and Nauman A. Expression of mutant thyroid hormone nuclear receptors is associated with human renal clear cell carcinoma. Carcinogenesis 23 (2002) 25-33
26. Kaneshige M., Kaneshige K., Zhu X., Dace A., Garrett L., Carter T.A., Kazlauskaite R., Pankratz D.G., Wynshaw-Boris A., Refetoff S., Weintraub B., Willingham M.C., Barlow C., and Cheng S. Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 13209-13214
27. Kim D., Pemberton H., Stratford A.L., Buelaert K., Watkinson J.C., Lopes V., Franklyn J.A., and McCabe C.J. Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells. Oncogene 24 (2005) 4861-4866
28. Kim C.S., Ying H., Willingham M.C., and Cheng S.-y. The pituitary tumor-transforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer. Carcinogenesis 28 (2007) 932-939
29. Lee J.M., Dedhar S., Kalluri R., and Thompson E.W. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell. Biol. 172 (2006) 973-981
30. Lei J., Mariash C.N., and Ingbar D.H. 3,3',5-Triiodo-L-thyronine up-regulation of Na,K-ATPase activity and cell surface expression in alveolar epithelial cells is Src kinase- and phosphoinositide 3-kinase-dependent. J. Biol. Chem. 279 (2004) 47589-47600
31. Lei J., Mariash C.N., Bhargava M., Wattenberg E.V., and Ingbar D.H. T3 increases Na-K-ATPase activity via a MAPK/ERK1/2-dependent pathway in rat adult alveolar epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 294 (2008) L749-L754
32. Li X., Lonard D.M., Jung S.Y., Malovannaya A., Feng Q., Qin J., Tsai S.Y., Tsai M.J., and O'Malley B.W. The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATP-independent manner by the REGgamma proteasome. Cell 124 (2006) 381-392
33. Li Z., Meng Z.H., Chandrasekaran R., Kuo W.L., Collins C.C., Gray J.W., and Dairkee S.H. Biallelic inactivation of the thyroid hormone receptor beta1 gene in early stage breast cancer. Cancer Res. 62 (2002) 1939-1943
34. Lin K.H., Shieh H.Y., Chen S.L., and Hsu H.C. Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol. Carcinog. 26 (1999) 53-61
35. Liu J., Stevens J., Rote C.A., Yost H.J., Hu Y., Neufeld K.L., White R.L., and Matsunami N. Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol. Cell 7 (2001) 927-936
36. Liu J., Wang H., Zuo Y., and Farmer S.R. Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin. Mol. Cell. Biol. 26 (2006) 5827-5837
37. Lonard D.M., and O'Malley B.W. Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol. Cell. 27 (2007) 691-700
38. McCabe C.J., Khaira J.S., Boelaert K., Heaney A.P., Tannahill L.A., Hussain S., Mitchell R., Olliff J., Sheppard M.C., Franklyn J.A., and Gittoes N.J. Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clin. Endocrinol. (Oxf.) 58 (2003) 141-150
39. Meier C.A., Dickstein B.M., Ashizawa K., McClaskey J.H., Muchmore P., Ransom S.C., Menke J.B., Hao E.H., Usala S.J., Bercu B.B., Cheng S.-y., and Weintraub B.D. Variable transcriptional activity and ligand binding of mutant beta 1,3,5,3'-triiodothyronine receptors from four families with generalized resistance to thyroid hormone. Mol. Endocrinol. 6 (1992) 248-258
40. Miyakawa M., Tsushima T., Murakami H., Wakai K., Isozaki O., and Takano K. Increased expression of phosphorylated p70S6 kinase and Akt in papillary thyroid cancer tissues. Endocrinol. J. 50 (2003) 77-83
41. Moon R.T., Bowerman B., Boutros M., and Perrimon N. The promise and perils of Wnt signaling through beta-catenin. Science 296 (2002) 1644-1646
42. Nelen M.R., van Staveren W.C., Peeters E.A., Hassel M.B., Gorlin R.J., Hamm H., Lindboe C.F., Fryns J.P., Sijmons R.H., Woods D.G., Mariman E.C., Padberg G.W., and Kremer H. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum. Mol. Genet. 6 (1997) 1383-1387
43. Neri L.M., Borgatti P., Capitani S., and Martelli A.M. The nuclear phosphoinositide 3-kinase/AKT pathway: a new second messenger system. Biochim. Biophys. Acta 1584 (2002) 73-80
44. O'Shea P.J., Harvey C.B., Suzuki H., Kaneshige M., Kaneshige K., Cheng S.-y., and Williams G.R. A thyrotoxic skeletal phenotype of advanced bone formation in mice with resistance to thyroid hormone. Mol. Endocrinol. 17 (2003) 1410-1424
45. Ono S., Schwartz I.D., Mueller O.T., Root A.W., Usala S.J., and Bercu B.B. Homozygosity for a dominant negative thyroid hormone receptor gene responsible for generalized resistance to thyroid hormone. J. Clin. Endocrinol. Metab. 73 (1991) 990-994
46. Parrilla R., Mixson A.J., McPherson J.A., McClaskey J.H., and Weintraub B.D. Characterization of seven novel mutations of the c-erbA beta gene in unrelated kindreds with generalized thyroid hormone resistance. Evidence for two "hot spot" regions of the ligand binding domain. J. Clin. Invest. 88 (1991) 2123-2130
47. Polakis P. Casein kinase 1: a Wnt'er of disconnect. Curr. Biol. 12 (2002) R499-R501
48. Polakis P. The many ways of Wnt in cancer. Curr. Opin. Genet. Dev. 17 (2007) 45-51
49. Puzianowska-Kuznicka M., Krystyniak A., Madej A., Cheng S.-y., and Nauman J. Functionally impaired TR mutants are present in thyroid papillary cancer. J. Clin. Endocrinol. Metab. 87 (2002) 1120-1128
50. Puzianowska-Kuznicka M., Nauman A., Madej A., Tanski Z., Cheng S., and Nauman J. Expression of thyroid hormone receptors is disturbed in human renal clear cell carcinoma. Cancer Lett. 155 (2000) 145-152
51. Refetoff S., Weiss R.E., and Usala S.J. The syndromes of resistance to thyroid hormone. Endocrinol. Rev. 14 (1993) 348-399
52. Ringel M.D., Hayre N., Saito J., Saunier B., Schuppert F., Burch H., Bernet V., Burman K.D., Kohn L.D., and Saji M. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res. 61 (2001) 6105-6111
53. Safer J.D., Colan S.D., Fraser L.M., and Wondisford F.E. A pituitary tumor in a patient with thyroid hormone resistance: a diagnostic dilemma. Thyroid 11 (2001) 281-291
54. Sap J., Munoz A., Schmitt J., Stunnenberg H., and Vennstrom B. Repression of transcription mediated at a thyroid hormone response element by the v-erb-A oncogene product. Nature 340 (1989) 242-244
55. Sardi S.P., Murtie J., Koirala S., Patten B.A., and Corfas G. Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain. Cell 127 (2006) 185-197
56. Sharma C., Pradeep A., Wong L., Rana A., and Rana B. Peroxisome proliferator-activated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway. J. Biol. Chem. 279 (2004) 35583-35594
57. Shepherd P.R., Nave B.T., Rincon J., Haigh R.J., Foulstone E., Proud C., Zierath J.R., Siddle K., and Wallberg-Henriksson H. Involvement of phosphoinositide 3-kinase in insulin stimulation of MAP-kinase and phosphorylation of protein kinase-B in human skeletal muscle: implications for glucose metabolism. Diabetologia 40 (1997) 1172-1177
58. Siesser W.B., Cheng S.-y., and McDonald M.P. Hyperactivity, impaired learning on a vigilance task, and a differential response to methylphenidate in the TRbetaPV knock-in mouse. Psychopharmacology (Berl.) 181 (2005) 653-663
59. Silva J.M., Dominguez G., Gonzalez-Sancho J.M., Garcia J.M., Silva J., Garcia-Andrade C., Navarro A., Munoz A., and Bonilla F. Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. Oncogene 21 (2002) 4307-4316
60. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K., Lin H., Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., Swedlund B., Teng D.H., and Tavtigian S.V. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15 (1997) 356-362
61. Suzuki H., Willingham M.C., and Cheng S.-y. Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid 12 (2002) 963-969
62. Thormeyer, D., Baniahmad, A., 1999, The v-erbA oncogene, Int. J. Mol. Med., 4, 351-8 (review).
63. Vasko V., Espinosa A.V., Scouten W., He H., Auer H., Liyanarachchi S., Larin A., Savchenko V., Francis G.L., de la Chapelle A., Saji M., and Ringel M.D. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 2803-2808
64. Verga Falzacappa C., Petrucci E., Patriarca V., Michienzi S., Stigliano A., Brunetti E., Toscano V., and Misiti S. Thyroid hormone receptor TRbeta1 mediates Akt activation by T3 in pancreatic beta cells. J. Mol. Endocrinol. 38 (2007) 221-233
65. Wallin G., Bronnegard M., Grimelius L., McGuire J., and Torring O. Expression of the thyroid hormone receptor, the oncogenes c-myc and H-ras, and the 90 kD heat shock protein in normal, hyperplastic, and neoplastic human thyroid tissue. Thyroid 2 (1992) 307-313
66. Weiss R.E., and Refetoff S. Resistance to thyroid hormone. Rev. Endocrinol. Metab. Disord. 1 (2000) 97-108
67. Wymann M.P., and Marone R. Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Curr. Opin. Cell. Biol. 17 (2005) 141-149
68. Xiao J.H., Ghosn C., Hinchman C., Forbes C., Wang J., Snider N., Cordrey A., Zhao Y., and Chandraratna R.A. Adenomatous polyposis coli (APC)-independent regulation of beta-catenin degradation via a retinoid X receptor-mediated pathway. J. Biol. Chem. 278 (2003) 29954-29962
69. Yen P.M. Physiological and molecular basis of thyroid hormone action. Physiol. Rev. 81 (2001) 1097-1142
70. Yen P.M. Molecular basis of resistance to thyroid hormone. Trends Endocrinol. Metab. 14 (2003) 327-333
71. Ying H., Furuya F., Zhao L., Araki O., West B.L., Hanover J.A., Willingham M.C., and Cheng S.-y. Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression. J. Clin. Invest. 116 (2006) 2972-2984
72. Ying H., Suzuki H., Furumoto H., Walker R., Meltzer P., Willingham M.C., and Cheng S.y. Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma. Carcinogenesis 24 (2003) 1467-1479
73. Yu R., Heaney A.P., Lu W., Chen J., and Melmed S. Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. J. Biol. Chem. 275 (2000) 36502-36505
74. Yu R., and Melmed S. Oncogene activation in pituitary tumors. Brain Pathol. 11 (2001) 328-341
75. Zhang X., Horwitz G.A., Heaney A.P., Nakashima M., Prezant T.R., Bronstein M.D., and Melmed S. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J. Clin. Endocrinol. Metab. 84 (1999) 761-767
76. Zimonjic D.B., Kato Y., Ying H., Popescu N.C., and Cheng S.-y. Chromosomal aberrations in cell lines derived from thyroid tumors spontaneously developed in TRbetaPV/PV mice. Cancer Genet. Cytogenet. 161 (2005) 104-109
77. Zou H., McGarry T.J., Bernal T., and Kirschner M.W. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285 (1999) 418-422